975.627℃ at 760 mmHg
Carfilzomib (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) is an anti-cancer drug acting as a selective proteasome inhibitor for the treatment of patients with multiple myeloma. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.
Carfilzomib Intermediates: CAS No.: 247068-85-5
, CAS No.: 868539-96-2